

Mair G, vonKummer R, Adami A, White PM, Adams ME, Yan B, Demchuk AM, Farrall AJ, Sellar RJ, Sakka E, Palmer J, Perry D, Lindley R, Sandercock PA, Wardlaw JM. [Arterial obstruction on computed tomographic or MR angiography and response to intravenous thrombolysis in ischemic stroke.](#) *Stroke* 2017, 48, 353-360.

Copyright:

© 2016 The Authors.

Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs-License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is non-commercial, and no modifications or adaptations are made

DOI link to article:

<https://doi.org/10.1161/STROKEAHA.116.015164>

Date deposited:

28/02/2017



This work is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International licence](#)

Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke

Grant Mair, MBChB; Rüdiger von Kummer, Prof Dr med; Alessandro Adami, MD; Philip M. White, MD; Matthew E. Adams, MBChir; Bernard Yan, MD; Andrew M. Demchuk, MD; Andrew J. Farrall, MD; Robin J. Sellar, MBBS; Eleni Sakka, MSc; Jeb Palmer; David Perry, BSc; Richard I. Lindley, MD; Peter A.G. Sandercock, DM; Joanna M. Wardlaw, MD; for the IST-3 Collaborative Group

Background and Purpose—Computed tomographic angiography and magnetic resonance angiography are used increasingly to assess arterial patency in patients with ischemic stroke. We determined which baseline angiography features predict response to intravenous thrombolytics in ischemic stroke using randomized controlled trial data.

Methods—We analyzed angiograms from the IST-3 (Third International Stroke Trial), an international, multicenter, prospective, randomized controlled trial of intravenous alteplase. Readers, masked to clinical, treatment, and outcome data, assessed prerandomization computed tomographic angiography and magnetic resonance angiography for presence, extent, location, and completeness of obstruction and collaterals. We compared angiography findings to 6-month functional outcome (Oxford Handicap Scale) and tested for interactions with alteplase, using ordinal regression in adjusted analyses. We also meta-analyzed all available angiography data from other randomized controlled trials of intravenous thrombolytics.

Results—In IST-3, 300 patients had prerandomization angiography (computed tomographic angiography=271 and magnetic resonance angiography=29). On multivariable analysis, more extensive angiographic obstruction and poor collaterals independently predicted poor outcome ($P<0.01$). We identified no significant interaction between angiography findings and alteplase effect on Oxford Handicap Scale ($P\geq 0.075$) in IST-3. In meta-analysis (5 trials of alteplase or desmoteplase, including IST-3, $n=591$), there was a significantly increased benefit of thrombolytics on outcome (odds ratio >1 indicates benefit) in patients with (odds ratio, 2.07; 95% confidence interval, 1.18–3.64; $P=0.011$) versus without (odds ratio, 0.88; 95% confidence interval, 0.58–1.35; $P=0.566$) arterial obstruction (P for interaction 0.017).

Conclusions—Intravenous thrombolytics provide benefit to stroke patients with computed tomographic angiography or magnetic resonance angiography evidence of arterial obstruction, but the sample was underpowered to demonstrate significant treatment benefit or harm among patients with apparently patent arteries.

Clinical Trial Registration—URL: <http://www.isrctn.com>. Unique identifier: ISRCTN25765518.

(Stroke. 2017;48:00-00. DOI: 10.1161/STROKEAHA.116.015164.)

Key Words: arteries ■ brain infarction ■ cerebral angiography ■ meta-analysis ■ stroke

Computed tomographic angiography (CTA) and magnetic resonance angiography (MRA) are increasingly used to assess arterial patency in patients with ischemic stroke.^{1,2}

Angiography may also improve selection of patients with ischemic stroke for treatment with intravenous thrombolytics. However, it is unclear if arterial obstruction, or collateral

Received August 18, 2016; final revision received November 1, 2016; accepted November 11, 2016.

From the Division of Neuroimaging Sciences (G.M., A.J.F., R.J.S., E.S., J.P., J.M.W.) and Division of Clinical Neurosciences (D.P., P.A.G.S.), University of Edinburgh, United Kingdom; Department of Neuroradiology, Dresden University Stroke Centre, Germany (R.v.K.); Stroke Center, Sacro Cuore-Don Calabria Hospital, Verona, Italy (A.A.); Stroke Research Group, Newcastle upon Tyne, United Kingdom (P.M.W.); National Hospital for Neurology and Neurosurgery, London, United Kingdom (M.E.A.); Neurovascular Research Group, Royal Melbourne Hospital, Australia (B.Y.); Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); and Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia (R.I.L.).

Guest Editor for this article was Louis Caplan, MD.

A list of all IST-3 Collaborative Group participants is given in the Appendix I in the [online-only Data Supplement](#).

The online-only Data Supplement is available with this article at <http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.116.015164/-/DC1>.

Correspondence to Joanna M. Wardlaw, MD, Division of Neuroimaging Sciences, Western General Hospital, Crewe Rd, Edinburgh EH42XU, United Kingdom. E-mail joanna.wardlaw@ed.ac.uk

© 2016 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Stroke is available at <http://stroke.ahajournals.org>

DOI: 10.1161/STROKEAHA.116.015164

supply, influences the response to intravenous thrombolytics. A retrospective stroke registry observed a trend for more favorable clinical outcome after intravenous alteplase in patients with intracranial arterial occlusion versus those with no/minimal obstruction in whom it was unclear if intravenous alteplase was beneficial or not.³

Few randomized controlled trials (RCTs) of intravenous thrombolytics included CTA or MRA to determine whether angiographic obstruction—occlusion or collateral supply modifies the treatment response. A pooled analysis of DIAS (Desmoteplase in Acute Ischemic Stroke), DIAS-2, and DEDAS (Dose Escalation of Desmoteplase for Acute Ischemic Stroke) demonstrated that patients with complete arterial occlusion or severe obstruction had better outcomes after desmoteplase than placebo, but in patients with minimal obstruction or normal arteries, there was no significant difference between desmoteplase versus placebo.⁴ In EPITHET (Echoplanar Imaging Thrombolytic Evaluation Trial), patients with middle cerebral artery (MCA) rather than internal carotid artery (ICA) obstruction demonstrated better outcome after intravenous alteplase, but they did not test for an alteplase–arterial patency interaction.⁵

The IST-3 (Third International Stroke Trial) was a large (n=3035) RCT that tested whether intravenous alteplase given within 6 hours of ischemic stroke improved functional outcome at 6 months compared with control.⁶ In IST-3, some centers routinely performed CTA or MRA prerandomization. As prespecified,⁷ we investigated whether arterial obstruction or collateral status on prerandomization CTA and MRA influenced outcome after alteplase versus control. In addition, we meta-analyzed all RCTs of intravenous thrombolytics in ischemic stroke with baseline angiography data.

Methods

Third International Stroke Trial

IST-3 was an international, multicenter, PROBE trial (prospective, randomized, open-label, blinded end point) of intravenous alteplase in acute ischemic stroke. Ethical approval was granted by the Multicentre Research Ethics Committees, Scotland (MREC/99/0/78) and by local ethics committees. Enrollment, randomization, data collection and analysis, and adherence to CONSORT (Consolidated Standards of Reporting Trials) recommendations have been published.^{6,8,9} Briefly, adults with acute stroke of any severity, in whom CT or MR imaging had excluded intracranial hemorrhage and structural stroke mimics, who did not meet the prevailing license criteria for alteplase but had no clear contraindication to treatment, were eligible for the trial if treatment could be started within 6 hours of known stroke onset. Informed consent was obtained for all patients. Baseline stroke severity before randomization was assessed with the National Institutes of Health Stroke Scale (NIHSS). After entry of baseline data, patients were randomly allocated to immediate intravenous alteplase (0.9 mg/Kg) or control. Functional outcome was assessed at 6 months with the Oxford Handicap Scale (OHS), which is similar to the modified Rankin Scale.

Angiographic Imaging in IST-3

IST-3 centers that routinely performed CTA or MRA in stroke submitted these images for assessment. Here, we include only IST-3 patients with angiography performed prerandomization. Images were anonymized and uploaded to a web-based rating platform, the Systematic Image Review System V2. Systematic Image Review System V2 provides secure anonymized image viewing via a browser

(www.neuroimage.co.uk) and simultaneously records the scan interpretation using a validated proforma^{10,11} (<http://www.sbirc.ed.ac.uk/research/imageanalysis.html>).

All angiographic imaging in IST-3 was assessed centrally by a panel of 10 experts in stroke imaging (7 neuroradiologists and 3 neurologists/stroke physicians). Readers were masked to all clinical, treatment, and functional outcome data and to imaging from different time points (concurrent plain scans were viewed with angiography). IST-3 angiography was analyzed independently from the plain CT and MR imaging scans of the main IST-3 trial.

Scan readers recorded the presence, location, and severity of all arterial obstructions, largest affected artery first plus ≤ 2 additional segments (Table 1 in the [online-only Data Supplement](#)). Locations were ICA, MCA, anterior cerebral artery, posterior cerebral artery, vertebral artery, or basilar artery. We grouped arterial segments as proximal (ICA, main stem MCA, vertebral artery, and basilar artery) or distal (Sylvian branch of MCA, anterior cerebral artery, and posterior cerebral artery).

Readers coded the focus of arterial obstruction using a modified Thrombolysis in Cerebral Infarction (TICI) and the IST-3 angiography scores.^{7,12} Both are scalar and range from occlusion (0), through decreasing grades of obstruction, to normal (3 for TICI and 4 for IST-3). For this analysis, we categorized the IST-3 score 0 to 2b and the TICI score 0 to 2a as obstruction and IST-3 score 3 to 4 and the TICI score 2b to 3 as patent.

Readers also coded the clot burden score in patients with anterior circulation obstruction (subtracts the sum of the number of arterial segments affected from 10,¹³ where score 0=all segments affected and 10=no segments affected) and the collateral vessel supply in patients with ICA or MCA obstruction (categorized as good where the entire MCA distal to obstruction reconstituted with contrast, moderate where there was some MCA branch reconstitution, or poor if only distal superficial branches reconstituted).¹⁴

We tested previously interobserver reliability for the IST-3 panel's CTA assessments (but because of the small number of cases, not MRA) on 15 representative scans,¹⁵ finding substantial agreement for arterial obstruction on TICI, IST-3 angiography, and clot burden scores (Krippendorff α =0.60, 0.66, and 0.63, respectively) and moderate agreement for collateral score (0.56).

Statistical Analysis: IST-3 Angiography Data

For univariate analysis of normally distributed data, we compared ratios and means with *t* tests; for nonparametric data, we used Mann–Whitney *U* tests to compare medians and Spearman ρ to assess for correlation. We used multifactor ANOVA to look for interactions between combinations of angiographic findings and OHS. To test for associations between angiography findings, alteplase versus control and outcome, we used multivariable ordinal regression to calculate common odds ratios (ORs) with OHS at 6 months as the dependent variable. We first tested the impact of different angiography characteristics on outcome individually, controlled for patient age, NIHSS, time from stroke onset to scan, and alteplase treatment allocation (here, OR <1 indicates worse outcome with alteplase). We then compared alteplase treatment effect on outcome (here, OR <1 favors control) for dichotomies (more normal versus less normal) of each angiography characteristic individually, controlled for patient age, NIHSS, and time from stroke onset to scan and tested for treatment interactions by comparing ORs between dichotomies. For this latter analysis only, we dichotomized clot burden and collateral scores as better (8–9 and good) versus worse (0–7 and moderate–poor, respectively).

Meta-Analysis

We identified all RCTs comparing intravenous thrombolytics with control among patients with baseline angiography after ischemic stroke from the Cochrane Collaboration systematic review on “Thrombolysis for Acute Ischaemic Stroke”¹⁶ and contacted investigators for additional data where necessary. We used the random effects method to perform 2 separate meta-analyses to obtain summary ORs

for the effect of intravenous thrombolytics (any formulation or dose) on outcome (OHS or mRS at 3–6 months) in patients with (1) arterial obstruction (IST-3 angiography score 0 to 2b or Thrombolysis in Myocardial Infarction 0–1 or 0–2) versus patent vessels (IST-3 angiography score 3–4 or Thrombolysis in Myocardial Infarction 2–3 or 3) and (2) ICA versus MCA obstruction, including tests for interactions between intravenous thrombolytics and arterial status on functional outcome. We tested for between-study heterogeneity using I^2 statistics. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for meta-analysis reporting (Appendix II in the [online-only Data Supplement](#)).

We used Comprehensive Meta-Analysis software (Biostat, Englewood, NJ) to compute summary ORs and test for interactions. We performed all other analyses using IBM SPSS Statistics software, version 20.0 (IBM Corporation, Armonk, NY). We considered $P < 0.05$ significant.

Results

Third International Stroke Trial

From 3035 IST-3 patients, 300 (9.9%) had prerandomization angiography, 271 with CTA, 29 with MRA. Compared with the full IST-3 trial, patients with angiography had less severe strokes at baseline (median NIHSS score of 9 versus 11; $P = 0.003$), had baseline scanning slightly later (mean 180 versus 164 minutes; $P < 0.0001$) and were randomized slightly later after stroke (mean 241 versus 231 minutes; $P = 0.019$), and had better 6-month outcomes (median OHS 3 versus 4; $P = 0.001$). There was no significant difference in age, sex, or treatment allocation between patients with angiograms versus the full IST-3 trial (Table II in the [online-only Data Supplement](#)). Among patients with angiography, there were no significant differences between alteplase and control groups (Table 1).

Table 1. Comparison of Baseline Data and Main Outcomes in IST-3 (Third International Stroke Trial) Patients With Angiography Allocated to Alteplase and Control (n=300)

	Alteplase, n=147	Control, n=153	P Value for Difference
Age, y, median (IQR)	81 (73–86)	80 (69–85)	0.274
Male sex (%)	63 (42.9)	69 (45.1)	0.697
Time from stroke onset to baseline scan, min, mean (SD)	184 (82)	175 (78)	0.344
Time from stroke onset to randomization, min, mean (SD)	243 (82)	238 (79)	0.584
Baseline NIHSS, median (IQR)	10 (5–17)	9 (5–16)	0.603
Clinical stroke syndrome ¹⁷ (%)			0.590
TACI	49 (33.3)	50 (32.7)	
PACI	64 (43.5)	68 (44.4)	
LACI	11 (7.5)	14 (9.2)	
POCI	23 (15.6)	20 (13.1)	
ASPECTS, ¹⁸ median (IQR)	10 (8–10)	10 (8–10)	0.914
6-mo OHS, median (IQR)	3 (1–5)	3 (1–5)	0.726
6-mo mortality (%)	32 (21.8)	35 (22.9)	0.819

ASPECTS indicates Alberta Stroke Program Early CT Score; IQR, interquartile range; LACI, lacunar infarct; NIHSS, National Institutes of Health Stroke Scale; OHS, Oxford Handicap Scale; PACI, partial anterior circulation infarct; POCI, posterior circulation infarct; and TACI, total anterior circulation infarct.

Angiography Findings: IST-3

In IST-3, 146 of 300 (48.7%) patients had intracranial arterial obstruction on angiography (Table 2). ICA (47/146=32.2%) or MCA mainstem (57/146=39.0%) obstruction was most common. For those with arterial obstruction, >1 arterial segment was affected in approximately half, 2 segments in 54 of 146 (37.0%), and 3 segments in 15 of 146 (10.3%). From 288 patients with an IST-3 Angiography score, 104 (36.1%) scored 0 to 2b, whereas 184 (63.9%) scored 3 to 4 (Table 2 for concurrent TIC1 scores). The median clot burden score was 8 (2 segments affected). Similar proportions had good (48/135=35.6%), moderate (37/135=27.4%), or poor (50/135=37.0%) collateral scores.

Angiography, Stroke Severity, and Functional Outcome: IST-3

On univariate analysis, all categories of angiographic abnormality were associated with significantly worse baseline stroke severity and poorer 6-month outcome ($P < 0.0001$ for most; Table III in the [online-only Data Supplement](#)). A 3-way ANOVA found no interaction between any combination of the effects of TIC1, clot burden, and collateral scores on OHS ($F = 0.814$; $P = 0.564$; Table IV in the [online-only Data Supplement](#)). In multivariable ordinal regression analysis, controlled for age, NIHSS, time from stroke onset to scan and alteplase treatment allocation; having a greater number of obstructed arterial segments (OR, 0.41; 95% confidence interval [CI], 0.22–0.76; $P = 0.005$), a worse clot burden score (OR, 0.78; 95% CI, 0.62–0.97; $P = 0.026$), or poorer collaterals (OR, 0.53; 95% CI, 0.32–0.85; $P = 0.009$) were all independent predictors of worse 6-month outcome, but not proximal versus distal (or ICA versus MCA) arterial obstruction, or the residual arterial caliber at the point of obstruction on IST-3 angiography or TIC1 scores (Table 3).

Angiography and Effect of Intravenous Alteplase: IST-3

In IST-3, in multivariable ordinal regression, we found no significant interactions between any individual angiogram feature and the effect of alteplase on 6-month OHS (Figure 1). There was a nonsignificant trend toward better outcomes after alteplase versus control among patients with obstructed (OR, 1.86; 95% CI, 0.76–4.53; $P = 0.171$) versus patent (OR, 0.72; 95% CI, 0.42–1.25; $P = 0.241$) arteries on the IST-3 angiography score, $P = 0.075$ for interaction (Figures 1 and 2).

Angiography and Effect of Intravenous Thrombolytics: Meta-Analysis of All Trials

We identified 11 RCTs of intravenous thrombolytics for ischemic stroke with baseline angiography (Figure I in the [online-only Data Supplement](#)) from which data were available for meta-analysis of 4 trials in addition to IST-3 (n=591). We included 2 trials of intravenous alteplase (288 patients from IST-3 and 87 from EPITHET¹⁹) and 3 trials of intravenous desmoteplase (216 patients from DIAS, DIAS-2, and DEDAS).^{20–22} Meta-analysis showed that patients with arterial obstruction were significantly more likely to have better functional outcome with intravenous thrombolytics versus control

Table 2. Angiography Findings for the 300 Patients Randomized in IST-3 With CTA or MRA

	Alteplase, n=147	Control, n=153
Angiographic obstruction, n=300*		
Yes	72	74
No	75	79
No. of obstructed arterial segments, n=146		
1	35	42
2	29	25
3	8	7
Largest arterial segment obstructed, n=146		
ICA	27	20
MCA mainstem	25	32
MCA Sylvian branch	15	16
Basilar	2	3
Vertebral	2	1
Other	1	2
ACA	0	0
PCA	0	0
Location of angiographic obstruction, n=142		
Distal vessel only	13	13
Proximal vessel only	21	25
Proximal and distal	36	34
IST-3 angiography score, n=288		
4	75	80
3	12	17
2b	7	9
2a	8	4
1	15	17
0	23	21
TICI score, n=288		
3	80	83
2b	12	20
2a	11	6
1	11	18
0	26	21
Clot burden score, n=123		
9	21	17
8	12	17
7	6	8
6	4	6
5	6	3
4	4	4
3	4	3
2	3	2

(Continued)

Table 2. Continued

	Alteplase, n=147	Control, n=153
1	1	1
0	0	1
Collateral score, n=135		
Good	22	26
Moderate	23	14
Poor	22	28

Clot burden and collateral scores were calculated only with anterior circulation obstruction. Obstruction was obscured or too peripheral for calculation of an IST-3 angiography, TICI or clot burden score in 12 cases. Not all patients with normal IST-3 angiography scores had normal TICI scores and vice versa. ACA indicates anterior cerebral artery; CTA, computed tomographic angiography; ICA, internal carotid artery; IST-3, Third International Stroke Trial; MCA, middle cerebral artery; MRA, magnetic resonance angiography; PCA, posterior cerebral artery; and TICI, Thrombolysis in Cerebral Infarction.

*Readers were asked is there an abnormal/occluded artery on CTA/MRA?

(OR, 2.07; 95% CI, 1.18–3.64; $P=0.011$) than were patients with patent arteries (intravenous thrombolytics versus control, OR, 0.88; 95% CI, 0.58–1.35; $P=0.566$), for interaction $P=0.017$ (Figure 3).

For meta-analysis of ICA versus MCA obstruction, data were only available from IST-3 and EPITHET ($n=135+54=189$, respectively) and we did not find any difference between response to intravenous thrombolytics in patients with ICA versus MCA obstruction (ICA obstruction: OR, 0.65; 95% CI, 0.06–6.89; $P=0.720$; MCA obstruction: OR, 1.92; 95% CI, 0.90–4.09; $P=0.090$) for interaction $P=0.391$ (Figure II in the online-only Data Supplement).

Discussion

This analysis of CTA and MRA data from 5 RCTs of intravenous thrombolytics (alteplase and desmoteplase), including IST-3, comprising 591 patients treated within 6 hours of stroke, indicates that patients with angiographic obstruction/occlusion benefit significantly more from intravenous thrombolytics than patients without arterial obstruction. Therefore, where endovascular therapy is not available,²³ intravenous thrombolytics remain an important treatment. The significant interaction between angiography appearance and intravenous thrombolytics does not mean that patients with normal baseline angiography gain no benefit from intravenous thrombolytics²⁴; the meta-analysis was neutral in this group, showing neither benefit or harm, but the sample is too small to exclude modest benefit or harm. It is important to remember that patients with normal angiograms may have arterial obstruction(s) too small to see on CTA/MRA, and intravenous thrombolytics may be beneficial in these patients.

In IST-3, we also demonstrate that having a greater number of obstructed arterial segments or poor collateral supply was associated with poor 6-month functional outcome, independent of stroke severity and alteplase treatment, that is, alteplase was less likely to improve outcome in these patients. Those with a greater number of obstructed segments may, therefore, have the most to gain from endovascular therapy, which several RCTs have recently shown to be superior to

Table 3. Multivariable Ordinal Regression Analyses Testing for Independent Associations Between Angiographic Findings in IST-3 and 6-Month Functional Outcome on the OHS

	Odds Ratio	95% Confidence Interval	P Value
Increased number of obstructed arterial segments, n=146	0.41	0.22–0.76	0.005
Obstructed proximal vs distal artery, n=142	0.45	0.20–1.02	0.055
Obstructed ICA vs MCA, n=135	0.85	0.40–1.81	0.679
Worse IST-3 angiography score, n=288	0.90	0.78–1.04	0.145
Worse TICl score, n=288	0.85	0.71–1.01	0.062
Worse Clot Burden Score, n=123	0.78	0.62–0.97	0.026
Poor Collateral Score, n=135	0.53	0.32–0.85	0.009

Odds ratio <1 indicates a worse outcome. Six-month OHS was the dependent variable for each separate model. Results are adjusted for patient age, time from stroke onset to scan, stroke severity (National Institutes of Health Stroke Scale), and alteplase treatment allocation. ICA indicates internal carotid artery; IST-3, Third International Stroke Trial; MCA, middle cerebral artery; OHS, Oxford Handicap Scale; and TICl, Thrombolysis in Cerebral Infarction.

intravenous alteplase alone among patients with angiography-confirmed proximal intracranial arterial obstruction.²⁵ Consistent with our results, post hoc analysis of one of these endovascular treatment trials demonstrated that patients with poor collateral supply had poorer outcomes than those with good collaterals.²⁶

We could not confirm in the meta-analysis that patients with MCA versus ICA obstruction responded differently to thrombolytics, but the sample available for this comparison was very small. In general, we were unable to identify available comparable trial data for most of the other angiography characteristics assessed in IST-3. To better understand thrombolysis–angiography interactions, future RCTs of acute stroke therapy with CTA or MRA should examine location, extent, completeness of arterial obstruction, and adequacy of

collaterals, to refine how these findings could help treatment decisions.

Strengths and Limitations

Strengths of IST-3 include our use of robust, validated methods for scan management, of scoring angiograms,⁷ with blinding of readers and moderate to substantial interobserver agreement.¹⁵ Limitations of IST-3, discussed previously, include the potential introduction of bias through its open design.⁶ Angiographic imaging was not a requirement of IST-3, but some centers performed baseline CTA or MRA for ischemic stroke routinely; therefore, the angiography analysis was preplanned to maximize knowledge gained from an RCT. The results of angiography were not used to determine trial eligibility, and at the time of IST-3 enrollment, there were virtually no data on how angiography results should be used in this context. Therefore, clinical uncertainty as to whether treatment with alteplase would be beneficial existed even for patients with large artery obstruction. Angiography was however performed in only 10% of IST-3 centers, potentially reflecting selection bias and restricting generalizability of the findings to all current stroke centers. Nevertheless, IST-3 angiography represents real-world practice, where nearly 50% had angiographic obstruction²⁷ and with 300 patients, is the largest angiography data set from an RCT of intravenous alteplase in ischemic stroke. Despite this, the wide CIs indicate that our sample is underpowered to estimate the effect of angiography findings on alteplase response. We used dichotomies of better versus worse angiography scoring to simplify scalar data in IST-3. We acknowledge that different dichotomies of the same scalar data could provide different results, but we felt that our technique nevertheless provided a meaningful and useable summary. For the meta-analysis, slight inconsistencies in angiogram scoring between trials mean that there is some overlap between categories (eg, Thrombolysis in Myocardial Infarction=2 is included in the better category for EPITHET but the worse category for the desmoteplase trials). Efforts to standardize angiogram rating in future trials should




Figure 1. IST-3 (Third International Stroke Trial), ordinal regression analyses, of the effect of alteplase treatment on outcome (Oxford Handicap Scale [OHS] as the dependent variable) in patients with more vs less normal results by different angiography features. Results represent odds ratio of better (right of vertical line) or worse (left of line) 6-month outcome with alteplase. Adjusted for age, time from stroke onset to scan, and stroke severity (National Institutes of Health Stroke Scale). ICA indicates internal carotid artery; MCA, middle cerebral artery; and TICl, Thrombolysis in Cerebral Infarction.




Figure 2. IST-3 (Third International Stroke Trial), bar charts comparing Oxford Handicap Scale (OHS) distribution for alteplase and control groups in those with (A) and without (B) arterial obstruction.

be encouraged because this will facilitate between-trial comparisons and meta-analysis.²⁸

Patients recruited in IST-3 after CTA or MRA were randomized and treated, on average, 10 minutes later than were those with only plain scans. The steep time dependency of alteplase

effects on outcome means that even this small delay could reduce the potential benefit of treatment,²⁹ particularly on a population level if angiography is performed nondiscriminately in all ischemic stroke patients. Efforts should be directed at minimizing delays attributable to obtaining angiography in stroke.




Figure 3. Meta-analysis of IST-3 (Third International Stroke Trial), EPITHET (Echoplanar Imaging Thrombolytic Evaluation Trial; alteplase), and the DIAS (Desmoteplase in Acute Ischemic Stroke), DIAS-2, and DEDAS (Dose Escalation of Desmoteplase for Acute Ischemic Stroke; desmoteplase) trials comparing the effect of intravenous thrombolytics on functional outcome between patients with arterial patency vs obstruction. Raw treatment data were unavailable for the Desmoteplase trials. Results represent odds ratio of better (right of vertical line) or worse (left of line) outcome after thrombolytics. Open circles represent arterial patency (test for heterogeneity, $I^2=0\%$). Closed circles represent arterial obstruction ($I^2=16\%$). TIMI indicates Thrombolysis in Myocardial Infarction.

Conclusions

Intravenous thrombolytic therapy is significantly more effective in improving functional outcome in patients presenting with ischemic stroke who have arterial obstruction than in those with apparently patent arteries on CTA or MRA. Intravenous thrombolytics, therefore, remain an important treatment option. The data are too sparse to determine, in this analysis, whether patients without apparent arterial obstruction benefit from intravenous thrombolytics, bearing in mind that these patients may have thrombus too small to detect on CTA or MRA.

Acknowledgments

This article acknowledges Dr Veronica Murray, IST-3 (Third International Stroke Trial) National Co-ordinator for Sweden, expert stroke neurologist, friend, and colleague, whose energy, enthusiasm, and huge contribution ensured the success of IST-3 and who died suddenly in late 2014. The IST-3 collaborative group thanks all study participants. We gratefully acknowledge the trial steering committee and national coordinators (Appendix I in the [online-only Data Supplement](#)). IST-3 centers providing baseline angiograms are listed in Appendix III in the [online-only Data Supplement](#). We are grateful to the EPITHET trial (Echoplanar Imaging Thrombolytic Evaluation Trial) investigators, especially Stephen M. Davis, Geoffrey A. Donnan, and Mark W. Parsons, for providing raw data for meta-analysis.

Sources of Funding

IST-3 angiography substudy (Third International Stroke Trial) was funded by the National Institute for Health Research (NIHR) Efficacy and Mechanisms Evaluation Panel (EME-08-43-52). Main IST-3 trial had many funders detailed in Appendix IV in the [online-only Data Supplement](#), primarily the UK Medical Research Council (MRC G0400069 and EME-09-800-15). Systematic Image Review System V2 (SIRS-2) development was funded by the Edinburgh MRC Hub for Trials Methodology Research funded by the UK MRC (G0800803).

Disclosures

R. von Kummer received fees from Lundbeck, Covidien, BrainGate, Boehringer Ingelheim, and Penumbra; Dr White from Microvention Terumo, and Codman; Dr Lindley from Boehringer Ingelheim and Covidien; and P.A.G. Sandercock from Boehringer Ingelheim. Dr Wardlaw received consultancy fees from Glaxo Smith Kline paid to the institution. The other authors report no conflicts.

References

- McDonald JS, Fan J, Kallmes DF, Cloft HJ. Pretreatment advanced imaging in patients with stroke treated with IV thrombolysis: evaluation of a multihospital data base. *AJNR Am J Neuroradiol*. 2014;35:478–481. doi: 10.3174/ajnr.A3797.
- Vagal A, Meganathan K, Kleindorfer DO, Adeoye O, Hornung R, Khatri P. Increasing use of computed tomographic perfusion and computed tomographic angiograms in acute ischemic stroke from 2006 to 2010. *Stroke*. 2014;45:1029–1034. doi: 10.1161/STROKEAHA.113.004332.
- Medlin F, Amiguet M, Vanacker P, Michel P. Influence of arterial occlusion on outcome after intravenous thrombolysis for acute ischemic stroke. *Stroke*. 2015;46:126–131. doi: 10.1161/STROKEAHA.114.006408.
- Fiebach JB, Al-Rawi Y, Wintermark M, Furlan AJ, Rowley HA, Lindström A, et al. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. *Stroke*. 2012;43:1561–1566. doi: 10.1161/STROKEAHA.111.642322.
- de Silva DA, Brekenfeld C, Ebinger M, Christensen S, Barber PA, Butcher KS, et al; Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators. The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). *Stroke*. 2010;41:295–299. doi: 10.1161/STROKEAHA.109.562827.
- IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. *Lancet*. 2012;379:2352–2363. doi: 10.1016/S0140-6736(12)60768-5.
- Wardlaw JM, von Kummer R, Carpenter T, Parsons M, Lindley RI, Cohen G, et al. Protocol for the perfusion and angiography imaging sub-study of the Third International Stroke Trial (IST-3) of alteplase treatment within six-hours of acute ischemic stroke. *Int J Stroke*. 2015;10:956–968. doi: 10.1111/j.1747-4949.2012.00946.x.
- Sandercock P, Lindley R, Wardlaw J, Dennis M, Lewis S, Venables G, et al; IST-3 Collaborative Group. Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke. *Trials*. 2008;9:37. doi: 10.1186/1745-6215-9-37.
- IST-3 Collaborative Group. Statistical analysis plan for the Third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial. *Int J Stroke*. 2012;7:186–187. doi: 10.1111/j.1747-4949.2012.00782.x.
- Wardlaw JM, Farrall AJ, Perry D, von Kummer R, Mielke O, Moulin T, et al; Acute Cerebral CT Evaluation of Stroke Study (ACCESS) Study Group. Factors influencing the detection of early CT signs of cerebral ischemia: an internet-based, international multiobserver study. *Stroke*. 2007;38:1250–1256. doi: 10.1161/01.STR.0000259715.53166.25.
- Wardlaw JM, von Kummer R, Farrall AJ, Chappell FM, Hill M, Perry D. A large web-based observer reliability study of early ischaemic signs on computed tomography. The Acute Cerebral CT Evaluation of Stroke Study (ACCESS). *PLoS One*. 2010;5:e15757. doi: 10.1371/journal.pone.0015757.
- Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, et al; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. *Stroke*. 2003;34:e109–e137. doi: 10.1161/01.STR.0000082721.62796.02.
- Puetz V, Dzialowski L, Hill MD, Subramaniam S, Sylaja PN, Krol A, et al; Calgary CTA Study Group. Intracranial thrombus extent predicts clinical outcome, final infarct size and hemorrhagic transformation in ischemic stroke: the clot burden score. *Int J Stroke*. 2008;3:230–236. doi: 10.1111/j.1747-4949.2008.00221.x.
- Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW. The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. *Brain*. 2009;132(pt 8):2231–2238. doi: 10.1093/brain/awp155.
- Mair G, von Kummer R, Adami A, White PM, Adams ME, Yan B, et al; IST-3 Collaborative Group. Observer reliability of CT angiography in the assessment of acute ischaemic stroke: data from the Third International Stroke Trial. *Neuroradiology*. 2015;57:1–9. doi: 10.1007/s00234-014-1441-0.
- Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2014;7:CD000213.
- Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. *Lancet*. 1991;337:1521–1526.
- Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. *Lancet*. 2000;355:1670–1674.
- Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. *Lancet Neurol*. 2008;7:299–309. doi: 10.1016/S1474-4422(08)70044-9.
- Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke*. 2005;36:66–73. doi: 10.1161/01.STR.0000149938.08731.2c.
- Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. *Stroke*. 2006;37:1227–1231. doi: 10.1161/01.STR.0000217403.66996.6d.

22. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. *Lancet Neurol*. 2009;8:141–150. doi: 10.1016/S1474-4422(08)70267-9.
23. Lindley RI, Levi CR. The spectacular recent trials of urgent neurointervention for acute stroke: fuel for a revolution. *Med J Aust*. 2015;203:58–60.
24. Lahoti S, Gokhale S, Caplan L, Michel P, Samson Y, Rosso C, et al. Thrombolysis in ischemic stroke without arterial occlusion at presentation. *Stroke*. 2014;45:2722–2727. doi: 10.1161/STROKEAHA.114.005757.
25. Rodrigues FB, Neves JB, Caldeira D, Ferro JM, Ferreira JJ, Costa J. Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis. *BMJ*. 2016;353:i1754.
26. Berkhemer OA, Jansen IG, Beumer D, Fransen PS, van den Berg LA, Yoo AJ, et al; MR CLEAN Investigators. Collateral status on baseline computed tomographic angiography and intra-arterial treatment effect in patients with proximal anterior circulation stroke. *Stroke*. 2016;47:768–776. doi: 10.1161/STROKEAHA.115.011788.
27. Hansen CK, Christensen A, Ovesen C, Havsteen I, Christensen H. Stroke severity and incidence of acute large vessel occlusions in patients with hyper-acute cerebral ischemia: results from a prospective cohort study based on CT-angiography (CTA). *Int J Stroke*. 2015;10:336–342. doi: 10.1111/ijss.12383.
28. Wintermark M, Albers GW, Broderick JP, Demchuk AM, Fiebach JB, Fiehler J, et al; Stroke Imaging Research (STIR) and Virtual International Stroke Trials Archive (VISTA)-Imaging Investigators. Acute stroke imaging research roadmap II. *Stroke*. 2013;44:2628–2639. doi: 10.1161/STROKEAHA.113.002015.
29. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. *Lancet*. 2014;384:1929–1935. doi: 10.1016/S0140-6736(14)60584-5.



Stroke

Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke

Grant Mair, Rüdiger von Kummer, Alessandro Adami, Philip M. White, Matthew E. Adams, Bernard Yan, Andrew M. Demchuk, Andrew J. Farrall, Robin J. Sellar, Eleni Sakka, Jeb Palmer, David Perry, Richard I. Lindley, Peter A.G. Sandercock and Joanna M. Wardlaw
for the IST-3 Collaborative Group

Stroke. published online December 22, 2016;

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2016 American Heart Association, Inc. All rights reserved.

Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://stroke.ahajournals.org/content/early/2016/12/22/STROKEAHA.116.015164>

Free via Open Access

Data Supplement (unedited) at:

<http://stroke.ahajournals.org/content/suppl/2017/01/19/STROKEAHA.116.015164.DC1>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:

<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Stroke* is online at:

<http://stroke.ahajournals.org/subscriptions/>

Arterial obstruction on CT or MR angiography and response to intravenous thrombolytics in ischemic stroke

Grant Mair (MBChB)¹, Rüdiger von Kummer (Prof.Dr.med.)²,
Alessandro Adami (MD)³, Philip M White (MD)⁴, Matthew E Adams (MBBChir)⁵,
Bernard Yan (MD)⁶, Andrew M Demchuk (MD)⁷, Andrew J Farrall (MD)¹,
Robin J Sellar (MBBS)¹, Eleni Sakka (MSc)¹, Jeb Palmer¹, David Perry (BSc)⁸,
Richard I Lindley (MD)⁹, Peter AG Sandercock (DM)⁸ and
Joanna M Wardlaw (MD)¹ for the IST-3 Collaborative Group¹⁰

1. Division of Neuroimaging Sciences, University of Edinburgh, UK.
2. Department of Neuroradiology, Dresden University Stroke Centre, Germany.
3. Stroke Center, Sacro Cuore-Don Calabria Hospital, Italy.
4. Stroke Research Group, Newcastle-upon-Tyne, UK.
5. National Hospital for Neurology and Neurosurgery, London, UK.
6. Neurovascular Research Group, Royal Melbourne Hospital, Australia.
7. Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Canada.
8. Division of Clinical Neurosciences, University of Edinburgh, UK.
9. Westmead Hospital Clinical School and The George Institute for Global Health, University of Sydney, Australia.
10. For IST-3 collaborative group, see Appendix I.

Corresponding Author:

Prof JM Wardlaw
Division of Neuroimaging Sciences
University of Edinburgh
Western General Hospital
Crewe Road
Edinburgh
EH4 2XU
UK

Phone: +441315372943
Fax: +441313325150
Email: joanna.wardlaw@ed.ac.uk

Table I. Scoring for angiogram characteristics in IST-3

Imaging Characteristic	Options Presented to Imaging Reader
Is there an Abnormal/ Occluded Artery on CTA/MRA	Yes No
Location of Angiographic Obstruction (3 Largest Arteries Selected)	Internal Carotid Artery (ICA) Middle Cerebral Artery (MCA) main stem MCA sylvian branch Anterior Cerebral Artery (ACA) Posterior Cerebral Artery (PCA) Vertebral Artery (VA) Basilar Artery (BA)
TICI (Modified) ¹	0 = No flow/patency 1 = Minimal flow/patency 2a = Partial flow <50% of expected territory 2b = Partial flow >50% of expected territory 3 = Complete flow/patency
IST-3 Angiography Score ² (Modified Mori) ³	0 = No patency 1 = Contrast penetrates obstruction but minimal enters distal artery 2a = Luminal patency of <50% with partial filling (< half) of major branches 2b = Luminal patency of <50% with partial filling (> half) of major branches 3 = Patency of >50% of lumen and filling of most branches 4 = Complete patency – normal
Clot Burden Score ⁴ (Anterior Circulation Only)	Six arterial locations are assessed for the presence of clot: Infralclnoid (1 point) and supraclnoid ICA (2 points) Proximal (2 points) and distal M1 MCA (2 points) M2 branches of MCA (1 point each) ACA (1 point)
Collateral Supply (MCA) ⁵	Good = Entire MCA distal to occlusion fills with contrast Moderate = Some of the MCA branches in the sylvian fissure fill with contrast Poor = Only distal superficial MCA branches fill with contrast

Footnote:

TICI = Thrombolysis in Cerebral Infarction.

The coding forms are available at www.sbirc.ed.ac.uk/research/imageanalysis.html

Table II. Clinical characteristics of the patients recruited into IST-3 with angiography compared to the full IST-3 trial.

	IST-3 Angiography Subgroup (n=300)	Remainder of IST-3 Group (n=2735)	p-value for Difference
Age (median, IQR)	80 (71-85) years	81 (72-86) years	0.510
Male Sex (%)	132 (44.0)	1333 (48.7)	0.119
Time from stroke onset to baseline scan (mean, SD)	180 (80) minutes	162 (71) minutes	<0.0001
Time from stroke onset to randomization (mean, SD)	241 (80) minutes	230 (72) minutes	0.019
Baseline NIHSS (median, IQR)	9 (5-17)	11 (6-18)	0.003
Treated with alteplase (%)	147 (49.0)	1368 (50.0)	0.738
Six-month OHS (median, IQR)	3 (1-5)	4 (2-6)	0.001
Independent at six-months (OHS 0-2, %)	134 (44.7)	954 (34.9)	0.001
Dead by six-months (%)	67 (22.3)	748 (27.3)	0.063

Footnote:

NIHSS = National Institutes of Health Stroke Scale. OHS = Oxford Handicap Scale.

IQR = Interquartile Range. SD = Standard Deviation.

Table III. Univariate associations between angiography findings, stroke severity and outcome in IST-3

Angiography Measure	Baseline NIHSS	Six-month OHS
Arterial Obstruction (n=146)	14 (8-20)*	5 (2-6)*
No Arterial Obstruction (n=154)	6 (4-10)	2 (1-4)
Obstructed Arterial Segment Number (n=146)	0.34*	0.37*
Obstructed Proximal Artery (n=113)	16 (9-21) †	5 (2-6) ‡
Obstructed Distal Artery Only (n=29)	12 (7-15)	3 (1-5)
IST-3 Angiography Score (n=288)	-0.52*	-0.34*
TICI Score (n=288)	-0.51*	-0.36*
Clot Burden Score (n=123)	-0.45*	-0.40*
Collateral Score (n=135)	0.41*	0.36*

Footnote:

Numbers represent median (interquartile range) or Spearman's correlation.

* p<0.0001, † p=0.023, ‡ p=0.002.

NIHSS = National Institutes of Health Stroke Scale. OHS = Oxford Handicap Scale.

TICI = Thrombolysis in Cerebral Infarction.

Proximal arteries include the internal carotid, middle cerebral mainstem, vertebral and basilar arteries. Distal arteries include the sylvian branch of middle cerebral, anterior cerebral and posterior cerebral arteries.

Variability in the total patient numbers reflects missing data in some categories; Clot Burden Score and Collateral Score was not calculated in all cases. Not all patients with normal IST-3 angiography score had normal TICI score and vice versa.

Table IV. Three-way analysis of variance (ANOVA) for interactions between combinations of angiographic findings and six-month OHS in IST-3

Angiographic Finding Combination	Degrees of Freedom	F	p-value
Clot Burden Score * TICl	18	1.306	0.217
Clot Burden Score * Collateral Score	9	1.480	0.176
TICl * Collateral Score	6	1.416	0.223
Clot Burden Score * TICl * Collateral Score	6	0.814	0.564

Footnote:

Due to collinearity between some of the angiographic measures, only one feature assessing extent of obstruction (Clot Burden Score rather than arterial segment number) and one feature assessing completeness of obstruction (TICl rather than IST-3 angiography score) were included in this ANOVA based on the strength of their associations with OHS on univariate analysis (Table III). There was also strong collinearity between location and extent of obstruction with very few multi-segment obstructions sited distally rather than proximally; location of obstruction was therefore also excluded from this ANOVA.

OHS = Oxford Handicap Scale. TICl = Thrombolysis in Cerebral Infarction.

Figure 1. PRISMA flow diagram demonstrating the identification and selection of trials for inclusion in the meta-analysis





Figure II. Meta-analysis of IST-3 and EPITHET comparing the effect of alteplase on outcome between patients with ICA versus MCA obstruction



Footnote:

Total patient numbers in each trial are provided, n.

Results represent odds ratio (95% confidence interval).

Vertical line represents an odds ratio = 1, i.e. no treatment effect on outcome. Left of the line indicates a worse outcome, right of the line a better outcome following alteplase.

EPITHET = Echoplanar Imaging Thrombolytic Evaluation Trial.⁷

ICA = Internal Carotid Artery (test for heterogeneity, $I^2 = 74\%$). MCA = Middle Cerebral Artery ($I^2 = 0\%$).

Appendix I. IST-3 Collaborative Group

For a complete list of all committees, please see the IST-3 primary publication in *The Lancet* (The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomized controlled trial. *Lancet* 2012;379:2352-63).

CO-INVESTIGATORS

Peter Sandercock, DM (University of Edinburgh, Scotland, co-chief Investigator); Richard I Lindley, MD (Sydney Medical School – Westmead Hospital and The George Institute for Global Health, University of Sydney, Australia, co-chief Investigator); and Joanna M Wardlaw, MD (University of Edinburgh, Scotland, co-chief Investigator for neuroradiology).

CONTRIBUTORS

Trial Steering Committee

Colin Baigent (University of Oxford, UK, independent chairman); David Chadwick (University of Liverpool, UK, independent chairman); Pippa Tyrrell (University of Manchester, UK, independent member); Gordon Lowe (University of Glasgow, UK, independent member); Martin Dennis (University of Edinburgh, Scotland); Geoff Cohen (University of Edinburgh, Scotland, statistician); Karen Innes (University of Edinburgh, Scotland, trial coordinator); Heather Goodare (lay representative).

National coordinators and associate national coordinators

Australia: Richard I Lindley, MD (Sydney Medical School – Westmead Hospital and The George Institute for Global Health, University of Sydney, Australia); Graeme J Hankey (Royal Perth Hospital, Perth). Austria: Karl Matz (Landeskrankenhaus Donauregion Tulln, Tulln), Michael Brainin. Belgium: AP. Canada: Gord Gubitz (Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax), Stephen J Phillips (Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax). Italy: Stefano Ricci (Department of Neurology ASL1, Ospedale, Citta' di Castello). Mexico: Antonio Arauz (Instituto Nacional de Neurologia, Mexico City). Norway: Eivind Berge (Oslo University Hospital, Oslo), Karsten Bruins Slot (Oslo University Hospital, Oslo). Poland: Anna Czlonkowska (Institute of Psychiatry and Neurology, Warsaw, and Medical University of Warsaw, Warsaw), Adam Kobayashi (Institute of Psychiatry and Neurology, Warsaw, Poland). Portugal: Manuel Correia (Hospital Geral de Santo Antonio, Porto). Switzerland: Phillippe Lyrer (University Hospital Basel, Basel), Stefan Engelter. Sweden: Veronica Murray (Karolinska Institutet, Stockholm), Andreas Terent, Bo Norrving, Per Wester. UK: Graham Venables (Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK).

CT and MRI reading panel

Joanna M Wardlaw, Andrew Farrall (University of Edinburgh, Scotland), Zoe Morris (University of Edinburgh, Scotland), Rüdiger von Kummer (Dresden University Stroke Centre, Germany), Lesley Cala (University of Western Australia, Crawley, Australia), Anders von Heijne (Danderyd Hospital, Stockholm, Sweden), Alessandro Adami (Sacro Cuore-Don Calabria Hospital, Verona, Italy), Andre Peeters (Cliniques Universitaires Saint-Luc, Bruxelles, Belgium), Gillian Potter (Salford Royal NHS Foundation Trust, England), Nick Bradey (Neuroradiology, James Cook University Hospital, South Tees Hospital NHS Trust, Middlesbrough, UK).

Angiography reading panel

Joanna M Wardlaw, Rüdiger von Kummer, Andrew Farrall, Robin Sellar (University of Edinburgh, Scotland), Alessandro Adami, Philip White (Newcastle University, UK), Andrew Demchuk (University

of Calgary, Canada), Matthew Adams (Great Ormond Street Hospital, London, UK), Grant Mair (University of Edinburgh, Scotland), Bernard Yan (The Royal Melbourne Hospital, Parkville, Australia).

IST-3 collaborative group and participating hospitals in each country

Figures in parentheses are the number of patients recruited in the country or by the centre.

UK (1447) Royal Hallamshire Hospital (118): G Venables, C Blank, H Bowler, C Doyle, K Endean, K Harkness, E Parker, M Randall. University Hospital of North Staffordshire (97): C Roffe, N Ahmad, A Arora, S Brammer, J Chembala, B Davies, S Ellis, E Epstein, K Finney, C Jackson, C Jadun, R Kinston, H Maguire, I Memon, I Natarajan, M Poulson, R Sanyal, S Sills, A Vreeburg, E Ward. Western General Hospital (95): P Sandercock, R Al-Shahi Salman, R Davenport, M Dennis, P Hand, S Hart, I Kane, S Keir, M MacLeod, L McKinlay, H Milligan, E Sandeman, J Stone, C Sudlow, P Taylor, J Wardlaw, C Warlow, W Whiteley, A Williams. The National Hospital for Neurology & Neurosurgery (84): M Brown, B Athwal, V Bassan, N Bhupathiraju, J Bowler, C Davie, D Doig, R Erande, S Gilbert, L Ginsberg, R Greenwood, S Gregoire, N Harding, N Losseff, R Luder, N Passeron, R Perry, P Rayson, R Simister, S Stone, D Werring. Arrowe Park Hospital (83): J Barrett, H Aitken, S Cherian, R Davis, S Downham, L Godd, V Gott, D Jose, V Little, D Lowe, L Luxford, M McGrory, P Owings, N Price, J Richards, G Sangster, J Sherlock, S Vargese, I Wakefield, P Weir. Southend University Hospital (77): P Guyler, T Attygale, S Chandler, L Coward, S Feasey, C Khuoge, T Loganathan, S Martin, A O'Brien, D Sinha, V Thompson, S Tysoe, R Walsh. Norfolk and Norwich University Hospital (67): K Metcalf, J Cochius, R Fulcher, N Gange, C Green, J Jagger, M Lee, P Myint, J Potter, G Ravenhill, S Shields, N Shinh, T Staunton, E Thomas, W Woodward, P Worth, N Wyatt. Nottingham City Hospital (63): W Sunman, P Bath, P Berman, J Clarke, C Gaynor, F Hammonds, R Harwood, K Mitchell, S Munshi, S Pacey, A Shetty, N Sprigg, H Stear, G Subramanian, A Wills. Guy's & St.Thomas Hospital (60): A Rudd, H Audebert, A Bhalla, J Birns, R Chowdhury, G Cluckie, I Davies, C Gibbs, P Holmes, N Mitchell, F Schiavone, E White, M Yeung. Darlington and Bishop Auckland Hospitals (56): A Mehrzad, V Baliga, E Brown, L Burnside, B Esisi, J Kent, P Orr, D Stead, E Wayman. University Hospital Aintree (46): R Durairaj, C Cullen, R Kumar, H Martin, D McDowell, A Sharma, V Sutton, R White. University Hospital of Wales (46): T Hughes, K Ali, J Anderson, K Baker, K Bethune, K Bethune, M Booth, M Cossburn, S Halpin, M Hourihan, E Marsh, K Peall, R Powell, H Shetty, M Wardle, M Williams. Derby Royal Hospital (37): K Muhiddin, J Beavan, M Clarke, R Donneley, S Elliott, P Fox, P Gorman, M Harper, M Mangoyana, I Memon, L Mills, L Wright. Addenbrookes Hospital (34): L Warburton, J Baron, P Barry, D Day, T Harold, P Martin, J Mitchell, E O'Brien, J Rycarte, M Turnham. St George's Healthcare NHS Trust (34): G Cloud, L Choy, B Clarke, C Griffin, O Halse, I Jones, F Kennedy, U Khan, R Lewis, A Loosemore, C Lovelock, H Markus, B Moynihan, J O'Reilly, O Paul, A Pereira, M Punter, P Rich, D Rolfe, F Schiavone. Royal Devon & Exeter Hospital (Wonford) (30): M James, J Bell, A Bowring, L Boxall, J Cageao, H Eastwood, S Elyas, F Hall, S Harries, A Hemsley, S Jackson, S Keenan, P Mudd, A Sekhar, D Strain, J Sword, N Wedge. Aberdeen Royal Infirmary (26): M MacLeod, M Bruce, A Joyson, M Kemp, K McMullan, J Reid, O Robb, J Webster, S Wilkinson. Hammersmith Hospitals & Imperial College (24): P Sharma, P Bentley, H Jenkins, A Kar, T Sachs. Northwick Park Hospital (20): D Cohen, R Bathula, J Devine, M Mpelembue. William Harvey Hospital (20): D Hargroves, I Balogun, L Cowie, A Maidment, D Rand, J Rowe, H Rudenko, D Smithard, L Wray. Scarborough Hospital (17): J Paterson, J Brown, J Hampton, S Jamieson, R Rose, A Volans. Countess of Chester Hospital NHS Foundation Trust (17): K Chatterjee, G Abbott, R Brookes, C Castle, C Kelly, S Leason, A Nallasivan, A Sen. Watford General Hospital (17): D Collas, M Cottle, N Damani, P Jacob, D Oza, D Werring. University Hospitals Coventry & Warwickshire NHS Trust (15): A Kenton, N Adab, L Aldridge, H Allroggen, Y Brown, R Cross, L Galvin, K Ghosh, A Grubneac, A Lindahl, H Mehta, M Pritchard, C Randall, P Ray, A Shehu, S Thelwell. Royal Bournemouth & Christchurch NHS Trust (12): D Jenkinson, J Bell, T Black, O David, J Kwan, A Orpen, C Ovington, D Tiwari, Z ud Din Babar. Leeds General Infirmary (12): A Hassan, A Bailey, J Bamford, C Bedford, R Bellfield, J Cooper, L Dunsmure, J Greig, M Keeling, L Mandizvidza, J Rankine, E Roberts, P Wanklyn, T Webb, S Williamson. York Health Services NHS Trust (12): J Coyle, S

Crane, C Croser, P Duffey, R Evans, E Iveson, M Keeling, G Kitching, M Porte, C Rhymes. Queen Elizabeth Hospital (Gateshead) (12): D Barer, M Armstrong, M Bokhari, T Cassidy, B McClelland. Queen Elizabeth The Queen Mother Hospital (10): G Gunathilagan, P DOLKE, S Jain, S Jones, A Maidment, L Rosser, G Thomas, C White. Worcestershire Royal Hospital (10): P Sanmuganathan, C Scholtz, E Stratford. Blackpool Victoria Hospital (10): M O'Donnell, H Goddard, G Hoadley, J Howard, S Leach, J McIlmoyle, A Stewart, A Strain. Basildon & Thurrock University Hospitals NHS FT (9): F Huwez, P Croot, N Gadi, N Mguni, U Umasankar. Royal Infirmary of Edinburgh (8): G Mead, B Chapman, A Coull, S Hart, A Kinnear, B Morrow, F Morrow. St Mary's Hospital (8): D Ames, J Ball, S Bannerjee, J Chataway. Yeovil District Hospital (8): K Rashed, C Buckley, D Donaldson, D Hayward, C Lawson. Luton and Dunstable Hospital (8): L Sekaran, K Bharaj, F Justin, G Jutlla, D Phiri, S Sethuraman, M Tate. Solihull Hospital, Heart of England NHS Trust (8): D Sandler, P Carr, G Jones, J Lyons, K Warren. King's College Hospital (7): L Kalra, A Davis, J Jarosz, D Manawadu, L Sztriha. Doncaster Royal Infirmary (7): D Chadha, A Holford, P Willcoxson. Royal United Hospital Bath (7): L Shaw, D Button, A Cunningham, L Dow, J Dutson, T Hall, C Hardy, N Jakeman, P Kaye, B Madigan, K O'Brien, D Pressdee, M Price, L Robinson, C Taylor, D Williamson. Birmingham Heartlands Hospital (6): D Sandler, P Carr, J Lyons, J McCormack, C Stretton. University Hospital North Durham (6): P Earnshaw, E Brown, S Bruce, C Church, S Desai, B Esisi, M Myint, N Watt. Wansbeck General Hospital (6): C Price, S Elliott, H Graham, R Lakey, K Mitchelson. Bristol Royal Infirmary (6): P Murphy, L Ball, S Caine, J Dovey, J Hughes, A Steele. Stepping Hill Hospital (6): K Dizayee, A Brown, T Chattopadhyay, J Cheetham, H Cochrane, A Datta, M Datta-chaudhuri, C Fox, D Kilroy, S Krishnamoorthy, F Levy, S Metha, P Ngoma, B Venkatesh. Princess Royal Hospital Brighton & Sussex University Hospitals Trust (5): K Ali, R Gautam, N Henderson, M Jones, S Murphy, G Spurling. Belfast City Hospital (5): I Wiggam, C Boyd, K Fullerton, P Gray, M Kinnaird, S MacNair, C Morgan, M Reid, S Tauro. Royal Liverpool University Hospital (5): S Loharuka, D Balmforth, P Cox, G Fletcher, A Ledger, A Manoj, M Wilkinson. City Hospital, Sandwell & West Birmingham Hospital (5): D Nicholl, S Clegg, S Hurdowar, S Kausar, K Law, A Singal, S Sturman. Royal London Hospital (4): P Gompertz, J Evanson, A Farrell, A Petrou, K Saastamoinen, T Sachs, A Salek-Haddadi, R Yadava. Sunderland Royal Hospital (4): J O'Connell, H Brew, S Butler, S Crawford, C Gray, D Gulliver, N Majmudar, R O'Brien. Morriston Hospital (4): M Wani, L Dacey, L Davies, R Evans, D Harris, T Jones, S Storton. Royal Preston Hospital (4): S Puneekar, A Ashton, S Duberley, H Emsley, C Gilmour, B Gregory, L Hough, S Philip, S Wuppalapati. The Royal Wolverhampton Hospitals NHS Trust (4): K Fotherby, P Bourke, D D'Costa, K Kauldhar, D Leung, R Lodwick, S McBride, D Morgan, M Qaiyum, G Sahota, M Srinivasan. Royal West Sussex NHS Trust, St Richard's Hospital (4): I Kane, N Chuter, L Garrad, M Hookway, S Ivatts, G Kennedy. Queen's Hospital Romford (4): K Darawil, L Al Dhahirl, S Andole, M Baig, P Dugh, K Dunne, H Kariuki, M Khan, S Rathnayaka. Ulster Hospital (3): M Power, K Dynan, J Finnerty, A Heaney, C Leonard, K McKnight, J Turkington, B Wroath. Great Western Hospital (3): B Dewan, S Cotton, M Gardiner, T Saunders, B Vincent. The Queen Elizabeth Hospital Birmingham (3): D Sims, P Guest, E Jones, J McCormack, D Nicholl, J Savanhu, R Tongue, M Willmot. Leicester General Hospital (3): D Eveson, S Dawson, M Dickens, M Fotherby, R Hunt, S Khan, T Kumar, R Marsh, A Mistri, T Robinson, J Thompson. Darent Valley Hospital, Dartford & Gravesham NHS Trust (3): P Aghoram, T Daniel, M Gatehouse, S Hussein, A Jackson, T Shanganya, E Strachan, G Tan. Nevill Hall Hospital, Aneurin Bevan Local Health (3): B Richard, S Elaine, S Hanson, S Mosely, H Reed, M Williams. Colchester Hospital University Foundation Trust (3): R Saksena, S Cook, D Demuran, M Keating, R Needle, V Paramsothy, A Sebastian, R Sivakumar, A Wright. Salford Royal Hospital Foundation NHS Trust (2): R Grue, E Barberan, C Dickson, C Douglas, J Jellicoe, T Marsden, J Priestley, E Quick, C Sherrington, A Singh, C Smith, J Stevens, P Tyrell, J Wainwright. Leicester Royal Infirmary (2): M Ardrion, J Birchall. Queen Elizabeth Hospital (Kings Lynn) (2): R Shekhar, C Barsted, S Coleman, S Fletcher, J Graham. John Radcliffe Hospital (2): A Buchan, J Hinkle, J Kennedy, A Manoj, M Westwood. Derriford Hospital (2): A Mohd Nor, S Alder, B Hyams, A Pace. West Cumberland Hospital (1): E Orugun, C Brewer, L Huntley, R Jolly, C Summers. Sandwell General Hospital (1): K Sharobeem, J Khaira, J Leahy, E Linehan, G Moore, J Rizkalla, J Wilkinson. Torbay Hospital (1): D Kelly, C Hilaire. Warrington & Halton Hospitals

NHS Foundation Trust (1): O Otaiku, L Connell, G Delaney-Sagar, G James, L Lomax, D Matthew, J Simpson, H Whittle. Medway Maritime Hospital (1): S Sanmuganathan, S Burrows, A Mahmood. Southampton General Hospital (1): G Durward, S Barker, J Cante, P Crawford, S Evans, V Pressly, N Weir. Victoria Hospital (1): V Cvoro, K McCormick. **Poland** (347) 2nd Department of Neurology, Institute of Psychiatry & Neurology (190): A Czlonkowska, J Bemberek, M Bilik, G Chabik, W Czepiel, J Dzierka, M Gluszkiewicz, K Grabska, B Janus-Laszuk, J Jedrzejewska, A Kobayashi, T Litwin, A Oskedra, A Piorkowska, M Skowronska, A Sliwinska, U Stepień. SPZZOZ w Sandomierzu (43): P Sobolewski, A Gajewska, M Grzesik, R Hatałska-Zerebiec, I Labudzka, B Loch, A Medrykowska, M Sledzinska, A Sobota, W Szczuchniak, G Wolak, I Zdyb. Medical University of Gdansk (35): W Nyka, D Gasecki, K Chwojnicky, A Gojska, B Karaszewski, G Kozera, M Kwarciany, M Nowak, M Swierkocka-Miastkowska, S Szczyrba, M Wisniewska, E Wnorowska. 1st Department of Neurology, Institute of Psychiatry & Neurology (25): P Richter, A Bochynska, M Chahwan, A Graban, R Rola. Military Medical Institute (24): A Stepień, B Brodacki, M Grotowska, J Kotowicz, J Staszewski, J Swistak, S Zaloga. Szpital Powiatowy (14): J Stoiński, K Czajkowska-Fornal, P Czubak, A Kaczor, J Kraska, E Nowakowska-Sledz, J Ozdoba-Rot, E Zawadzka. Szpital Specjalistyczny w Konskich (8): M Fudala, D Adamczyk, W Broła, I Guldzińska, K Kaluzny, M Kucharska-Lipowska, M Mosiolek, M Polewczyk, M Ziomek. Central University Hospital (7): G Opala, M Arkuszewski, M Kudlacik, P Malgorzata, M Swiat. SPSK im. Prof. W. Orłowskiego CMKP (1): U Fiszer, M Lenska-Mieciek. **Italy** (326) Ospedale Di Citta' di Castello (62): S Cenciarelli, A Barilaro, R Conduro, F Coppola, S Dioguardi, E Gallinella, A Mattioni, C Menichetti, S Ricci. Nuovo Ospedale Civile "S. Agostino-Estense" (40): F Casoni, M Bacchelli, M Cavazzuti, M Malagoli, A Zini. Ospedale Beato Giacomo Villa - Citta' della Pieve (36): G Benemio, M Celani, R Allegrucci, V Bondo, S Cupella, L Guerra, S Guerrieri, C Ottaviani, E Righetti, C Rossi, N Sacchi, M Scucchi, V Stefanini. Ospedale Di Branca (36): T Mazzoli, A Bigaroni, L Greco, R Paris, P Parise, S Ricci. A.O. Niguarda Ca'Granda (25): A Ciccone, L Basso, R Causarano, P Doneda, E Ferrante, A Gatti, A Guccione, A Gullo, F Imbesi, S Jann, R Marazzi, E Moro, C Motto, D Parodi, A Protti, M Riva, A Rosiello, I Santilli, R Sterzi, P Tiraboschi, G Venturelli. R. Guzzardi Hospital - Vittoria (RG) (19): F Iemolo, R Campagna, G Campagnolo, A Carnemolla, N D'Apico, G D'Asta, S Giannarita, A Giordano, E Sanzar. Ospedale Regionale di Aosta (17): E Bottacchi, S Cordera, G Corso, M Di Giovanni, G Giardini, C Lia, T Meloni, M Pesenti Campagnoni, P Tosi. Ospedale Sacro Cuore - Negrar Verona (12): A Adami, G Rossato, T Zuppini. Ospedale Maggiore - Bologna (12): G Procaccianti, T Sacquegna. Università degli Studi di Genova (11): C Gandolfo, M Balestrino, C Bruno, L Castellan, M Del Sette, A Ferrari, C Finocchi, N Reale, D Rizzi. Ospedale Civile S. Andrea (9): M Del Sette, L Benedetti, C Capellini, E Carabelli, E Cibeì, M Godani, G Guariglia, E Landini, A Mannironi, B Nucciarone, S Parodi, S Tonelli, E Traverso, D Zito. Ospedale S. Giovanni Battista - Foligno (8): P Brustenghi, F Corea, O Flamini, S Lolli, G Pelliccia, R Ricci, S Stefanucci, M Zampolini. Ospedale a Vibo Valentia (8): D Consoli, F Galati, P Postorino. Azienda Ospedaliero-Universitaria "Ospedali Riuniti" di Foggia (8): G Rinaldi, E Carapelle, G Grilli, M Guido, L Specchio. Ospedale Valduce di Como (8): N Checcarelli, G Borin, L Chiveri, R Clerici, E Corengia, L Gandola, P Garavaglia, M Guidotti, A Martegani, M Mauri, F Muscia, F Raudino. Ospedale di Cattinara - Trieste (4): F Chiodo Grandi, A Bratina, N Carraro, M Gaio, A Granato, N Koscica, M Naccarato, V Sarra, P Schincariol, C Vilotti, Z Zugna. Clinica Dr Pederzoli Spa (4): D Idone, C Bonato, E De Angelis, A Forgiione, M Gambera, F Recchia, S Tamburin, P Tinazzi Martini, G Zanette. Ospedale Civile San Matteo Degli Infermi - Spoleto (2): S Grasselli. Ospedale Silvestrini - Perugia (2): G Agnelli, A Andrea, A Billecia, V Caso, V Casso, R Fabiola, P Fanelli, M Paciaroni, B Sergio, M Vemti. Mater Salutis Hospital, Legnago VR (2): M Silvestri, L Altarini, A Bonfante, M Bonornetti, B Costa, N D'Attoma, N Deluca, F Frattini, R Niego, D Rafaele, V Ravenna, M Turazzini. Ospedale Guglielmo da Saliceto - Piacenza (1): S Cammarata. **Sweden** (297) Uppsala University Hospital (100): E Lundström, L Jonsson, U Söderström, A Terént. Danderyd Hospital (46): V Murray, A Alvelius, M Arbin von, I Dalenbring, Å Doverhall, Å Franzén-Dahlin, N Greilert, M Hallberg, A Heijne von, E Isaksson, H Kumpulainen, A Laska, A Lundström, C Martin, J Muhrbeck, E Näslund, N Ringart, E Rooth, R Undén, P Waldenström. Hassleholm Hospital (29): M Esbjörnsson, M Petranek. Karnsjukhuset (25): B Cederin, E Bertholds, A Elgåsen, T Johansson, B

Witteborn. Koping Hospital (20): M Kwiatkowska, E Gustafsson, T Noren, J Saaf. Mora Hospital (17): J Teichert, M Bertilsson, S Nilsson, S Oestberg. Lidköping Hospital (11): L Welin, K Fredricson, L Pehn. Falu Hospital (11): J Hambræus, I Lonn. Capió S:t Goran Hospital (9): B Hojeberg, A Adolfsson, M Anzen. Västervik Hospital (5): T Wallen, R Schloenzig, P Söderström, A Wennerberg. University Hospital MAS (5): F Buchwald, K Abul-Kasim, A Berkeskold, J Petersson, E Poromaa. University Hospital of Northern Sweden (4): P Wester, R Backlund, A Sjöström. Helsingborgs lasarett (4): B Hedström, E Campbell, K Johnsson, B Karlsson, N Lekokotla, C Lundahl, A Risedal, P Sandgren, A Svensson. Visby Hospital (4): S Bysell, E Smedberg, A Vestberg Bysell. Sundsvall Hospital (3): V Sjögren, B Högvall. University Hospital Lund (2): G Andsberg, T Cronberg, A Lindgren. Västera Hospital (1): H Wannberg, F Ax, L Nyren. Karlstad Central Hospital (1): J Sanner, H Andersson, F Andler, S Holmgård, R Johansson, I Magnussan, K Nilsson, J Rådberg. **Norway** (204) Trondheim University Hospital (69): B Indredavik, H Ellekjær, A Østvik, G Rohweder, D Steckhan, J Storvold. Oslo University Hospital Sykehus (66): E Berge, Y Rønning, R Aakvik, K Bruins Slot, G Knutsen, M Moxness, R Pettersen, T Wyller. University Hospital of North Norway (23): C Wahl, O Iversen, S Johnsen, B Norderhus, L Steffensen, E Stensland. Kongsvinger Hospital (13): T Asak, J Aaseth, T Rotnes, J Sparby, S Wetterhus. Levanger Hospital (9): H Hallan, A Aardal, T Graven, H Hansbakk Skjetne, B Klykken, K Lindqvist, A Tommy. University Hospital of North Norway (8): T Engstad, M Antonsen, R Bajic, W Fønnebø, S Hykkerud, I Lyngmo, A Nyrnes, S Rogne, S Sparr. Harstad Hospital (7): O Kildahl-Andersen, K Pedersen, H Ulrichsen. Ålesund Hospital (4): O Skogen, I Alnes, R Hukari, Y Seljeseth, P Vadset. Asker and Bærum Hospital (2): G Knutsen, B Fure, H Ihle-Hansen, N Johnsen, L Kornberg. Namsos Hospital (2): S Schuler, M Heibert. Volda Hospital (1): M Lillebø, O Aasen, I Eskeland, T Hamre, S Hareide, H Helset, K Kolnes, B Lødemel, H Ose Velle, S Reite, E Velle. **Australia** (179) Nambour General Hospital (51): R Grimley, E Ahern, C Cocks, M Courtney, R Devin, J Endacott, C Fawcett, V Harrington, C Johnston, M Koltermann, S Murray, K Ng, G Styles, A Tampiyappa. John Hunter Hospital (29): C Levi, K Chung, L Dark, M Evans, Y Gawarikar, E Kerr, A Loisselle, F Miteff, A Moore, W O'Brien, M Parsons, D Quain, A Royan, M Russell, N Spratt. Gosford Hospital (24): J Sturm, D Crimmins, D Griffiths, P Kavelieros, J Kinsella, A Malhotra, B O'Brien, A Schutz, M Webb, S Whyte, V Zenteno. Westmead Hospital (16): R Lindley, A Bleasel, N Cordato, A Duggins, V Fung, L Gomes, N Ingham, J Ip, P Landau, J Morris, S Vucic. Royal Perth Hospital (15): G Hankey, A Claxton, N Lillywhite. The Canberra Hospital (12): C Lueck, C Andrews, G Danta, C Das, I Harvey, A Hughes, C McColl, A Oon, R Tuck. Royal Brisbane and Women's Hospital (10): S Read, M Badve, M Broad, G Cadigan, H Cavanagh, J Chalk, D Copsinis, K Etherington, R Henderson, R Hull, J O'Sullivan, J Pandian, L Ross-Lee, M Roxas, N Sheikh, G Skinner, A Wong. Austin Health - Repatriation Campus (8): H Dewey, A Brodtmann, G Donnan, A Hughes, M Karonen, H Ma, T Mulcahy, S Petrolo, L Walker, D Young, J Zavala. Nepean Hospital (7): M Thieben, C Harris, M Krause, S Lane, H Park, M Shaffi, J Wood. Box Hill Hospital (7): C Bladin, A Buckland, K Coughlan, B Coulton, A Gilligan, P Lee, S Mullen, Z Ross, P Sien Loh, C Szoek. **Portugal** (82) UAVC. Centro Hospitalar de Trás-os-Montes e Alto Douro (42): M Silva, F Afonso, J Gabriel, P Guimarães, A Velon. Hospital Pero da Covilhã (19): M Castelo-Branco, F Alvarez, V Branco, C Coxo, P Goulao, D Leal, S Morgado, R Oliveira, F Paiva, A Rodrigues, M Simoes. Hospital de Santo António (12): G Lopes, T Almeida, M Cardoso, J Chaves, C Correia, M Correia, J Damásio, R Felgueiras, J Pereira, A Tuna. Hospital S.Marcos (9): C Ferreira, E Lourenco, A Machado, R Mare, J Rocha. **Belgium** (73) Cliniques Universitaires St Luc (73): A Peeters. **Austria** (46) Landeskrankenhaus Donauregion Tulln (34): K Matz, M Brainin, G Funk, V Reiner-Deitemyer. Krankenhaus Der Barmherzigen Bruder Wien (9): J Ferrari, A Flamm-Horak, G Gruber, R Rattinger. Krankenhaus Göttlicher Heiland (3): W Muellbacher, D Doppelbauer, R Kalchmayr, W Schima, T Wieser, M Zart. **Switzerland** (23) Universitätsspital Basel (22): P Lyrer, L Bonati, S Engelter, F Fluri, S Muller, E Radue, A Tiemessen, L Walz, F Weisskopf, S Wetzler. Universitätsspital Zürich (1): A Luft, D Fetz, B Hertler, A Pangalu. **Canada** (8) QEII Health Sciences Centre (8): G Gubitza, P Boulton, J Jarrett, J Moeller, S Phillips. **Mexico** (3) Instituto Nacional de Neurologia y Neurocirugia MVS (3): A Arauz, L Bermudez, J Calleja, R Garcia.

Appendix II. PRISMA 2009 checklist for meta-analysis⁸

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	iii
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	1
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	2
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for	6

		each meta-analysis.	
Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9, Figure I
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9, Figures 3 & II
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Figures 3 & II
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	14

Appendix III. Centres that provided baseline CT or MR angiography in IST-3

Angiography data for the 300 cases used in these analyses came from the following Principle Investigators at their respective centres (n):

Prof Martin Brown, The National Hospital for Neurology & Neurosurgery, London, UK (68); Prof Anna Czlonkowska, 2nd Department of Neurology, Institute of Psychiatry & Neurology, Warsaw, Poland (30); Dr Erik Lundström, Uppsala University Hospital, Sweden (24); Dr Andre Peeters, Cliniques Universitaires St. Luc, Brussels, Belgium (20); Prof Philippe Lyrer, Universitätsspital Basel, Switzerland (18); Dr Jonathan Sturm, Gosford Hospital, Australia (13); Prof Christine Roffe, University Hospital of North Staffordshire, Stoke-on-Trent, UK (12); Dr Chris Levi, John Hunter Hospital, Newcastle, Australia (12); Dr Gaetano Procaccianti, Ospedale Maggiore, Milan, Italy (11); Dr Federica Casoni, Nuovo Ospedale Civile, Modena, Italy (11); Dr Stein Harald Johnsen, University Hospital Northern Norway (10); Dr Magnus Esbjornsson, Hassleholm Hospital, Sweden (10); Dr Bent Indredavik, St Olavs Hospital, University Hospital of Trondheim, Norway (9); Dr Karl Matz, Landesklinikum Donauregion Tulln, Austria (8); Dr David Hargroves, William Harvey Hospital, Ashford, UK (7); Dr Pankaj Sharma, Hammersmith Hospitals & Imperial College, London, UK (7); Prof Peter Sandercock, Western General Hospital, Edinburgh, UK (5); Dr Eivind Berge, Ullevål University Hospital, Oslo, Norway (3); Dr Patrick Gompertz, The Royal London Hospital, Barts and The London NHS Trust, UK (3); Professor Chris Bladin, Box Hill Hospital (Monash University), Australia (3); Dr Liz Warburton, Addenbrooke's Hospital, Cambridge, UK (2); Dr Stephen Read, Royal Brisbane and Women's Hospital, Australia (2); Dr Fabio Chiodo Grande, Ospedale di Cattinara, Trieste, Italy (1); Prof Graeme Hankey, Royal Perth Hospital, Australia (1); Prof Lalit Kalra, King's College Hospital, London, UK (1); Dr Gunaratnam Gunathilagan, Queen Elizabeth the Queen Mother Hospital, Margate, UK (1); Dr Odd Kildahl-Andersen, Harstad Sykehus, Norway (1); Prof Walenty Michal Nyka, Dr Dariusz Gasecki, Medical University of Gdansk, Poland (1); Dr Yngve Müller Seljeseth, Aalesund Sjukehus, Norway (1); Prof Per Wester, University Hospital of Northern Sweden (1); Prof Carlo Gandolfo, Università degli Studi di Genova, Dipartimento di Neuroscienze Oftalmologia e Genetica, Italy (1); Dr Paul Guyler, Southend University Hospital, Westcliff-on-Sea, UK (1); Dr David Nicholl, City Hospital, Sandwell & West Birmingham Hospitals NHS Trust, UK (1); Prof Andreas Luft, Universitätsspital Zürich, Switzerland (1).

Appendix IV. Funding sources for IST-3

The start-up phase of IST-3 was supported by a grant from the Stroke Association, UK (TSA 04/99). The expansion phase was funded by the Health Foundation UK (2268/1282). The scan reading development was funded by Chest, Heart Stroke Scotland (R100/7).

The main phase of the trial is funded by: *UK Medical Research Council* (MRC) (grant numbers G0400069 and EME 09-800-15) and managed by the *National Institute for Health Research* (NIHR) on behalf of the MRC-NIHR partnership; the Research Council of Norway; Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden; the Swedish Heart Lung Fund; The Foundation of Marianne and Marcus Wallenberg, Stockholm County Council; Karolinska Institute Joint ALF-project grants Sweden, the Polish Ministry of Science and Education (grant number 2PO5B10928); the Australian Heart Foundation; Australian *National Health and Medical Research Council* (NHMRC); the Swiss National Research Foundation; the Swiss Heart Foundation; the Foundation for Health and Cardio-/Neurovascular Research, Basel, Switzerland; the Assessorato alla Sanita, Regione dell'Umbria, Italy; and, Danube University, Krems, Austria.

Boehringer-Ingelheim GmbH donated drug and placebo for the 300 patients in the double-blind phase, but thereafter had no role whatsoever in the trial.

The UK Stroke Research Network (SRN study ID 2135) adopted the trial in 01/05/2006, supported the initiation of new UK sites, and in some centres, and, after that date, data collection was undertaken by staff funded by the network or working for associated NHS (National Health Service) organisations.

IST-3 gratefully acknowledges the extensive support of the NIHR Stroke Research Network, NHS Research Scotland (NRS), through the Scottish Stroke Research Network, and the National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC).

The central imaging work was undertaken at the Brain Imaging Research Centre (www.bric.ed.ac.uk), a member of the Scottish Imaging Network A Platform for Scientific Excellence (SINAPSE) collaboration (www.sinapse.ac.uk), at the Division of Clinical Neurosciences, University of Edinburgh. SINAPSE is funded by the Scottish Funding Council (SFC) and the Chief Scientist Office of the Scottish Executive (CSO).

Additional support was received from Chest Heart and Stroke Scotland, DesAcc, University of Edinburgh, Danderyd Hospital Research & Development Department, Karolinska Institutet, Oslo University Hospital, and the Dalhousie University Internal Medicine Research Fund.

References

1. Higashida RT, Furlan AJ. Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke. *Stroke*. 2003;34:1923-1924
2. Wardlaw JM, von Kummer R, Carpenter T, Parsons M, Lindley RI, Cohen G, et al. Protocol for the Perfusion and Angiography Imaging Sub-Study of the Third International Stroke Trial (Ist-3) of Alteplase Treatment within Six-Hours of Acute Ischemic Stroke. *Int J Stroke*. 2015;10:956-968
3. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, et al. Intravenous Recombinant Tissue Plasminogen Activator in Acute Carotid Artery Territory Stroke. *Neurology*. 1992;42:976-982
4. Puetz V, Dzialowski I, Hill MD, Subramaniam S, Sylaja PN, Krol A, et al. Intracranial Thrombus Extent Predicts Clinical Outcome, Final Infarct Size and Hemorrhagic Transformation in Ischemic Stroke: The Clot Burden Score. *Int.J.Stroke*. 2008;3:230-236
5. Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW. The Independent Predictive Utility of Computed Tomography Angiographic Collateral Status in Acute Ischaemic Stroke. *Brain*. 2009;132:2231-2238
6. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for Acute Ischaemic Stroke. *Cochrane.Database.Syst.Rev*. 2014;7:CD000213
7. Davis SM, Donnan G, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of Alteplase Beyond 3 H after Stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (Epithet): A Placebo-Controlled Randomised Trial. *Lancet Neurol*. 2008;7:299-309
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The Prisma Statement. *BMJ*. 2009;339:b2535